Abstract A series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones were synthesized and their anti-HIV-1 activities were evaluated. Most of these compounds were highly active against wild-type (WT) HIV-1 strain (IIIB) with EC 50 values in the range of 0.0038e0.4759 mmol/L. Among those compounds, I-11 had an EC 50 value of 3.8 nmol/L and SI (selectivity index) of up to 25,468 indicating excellent activity against WT HIV-1. In vitro anti-HIV-1 activity and resistance profile studies suggested that compounds I-11 and I-12 displayed potential anti-HIV-1 activity against laboratory adapted strains and primary isolated strains including different subtypes and (K103N þ Y181C) . The activity against reverse transcriptase (RT) was also evaluated for those compounds. Both I-11 and I-12 obtained sub-micromolar IC 50 values showing their potential in RT inhibition. The pharmacokinetics examination in rats indicated that compound I-11 has acceptable pharmacokinetic properties and bioavailability. Preliminary structureeactivity relationships and molecular modeling studies were also discussed.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are indispensable component of highly active antiretroviral therapy (HAART) that is widely used in the clinical treatment of HIV-1-infected patients 1e3 . Currently, five NNRTIs have been approved for clinical use: nevirapine (NVP), delavirdine (DLV), efavirenz (EFV), etravirine (ETR, TMC125), and rilpivirine (RPV, TMC278) 4, 5 . However, therapeutic effectiveness of these available drugs has been limited to a certain extent by the emergence of drug-resistant viruses and potentially severe side effects with longterm clinical use 6e8 . As a result, discovery of novel NNRTIs candidates with better resistance profiles and improved safety and tolerability is a continuous goal of drug development 9e13 . Among NNRTIs of clinical interest, 2-alkylsulfanyl-6-benzyl-3,4-dihydropyrimidin-4(3H)-ones (S-DABOs) occupy a significant place for their unique antiviral potency, high specificity and low toxicity 14e16 . Studies on S-DABOs suggested that an alkyl/ arylthio substituent at the C2 position, an aromatic ring linked through a methlyene bridge to the C6 position and the unmodified NHCO fragment constituting the N3 and C4 positions of the prymidine ring are structural determinants for the antiviral activity of these compounds 17e20 . The key interactions of S-DABOs with HIV-1 reverse transcriptase (RT) residues could be summarized as Fig. 1 .
Previous research efforts in our lab led to the identification of a series of oxophenethyl-S-DABOs derivatives with significant anti-HIV-1 activity 21e24 . Especially, by replacing the C6-arylring with a C6-cyclohexylmethyl moiety, a new series oxophenethyl-SDACOs of NNRTIs with higher potent and specificity was obtained 25 . The most promising compound DB02 exhibited potent anti-HIV-1 activity against laboratory adapted strains and primary isolated strains (EC 50 s (concentrations inhibiting virus replication by 50%) range from 2.40 to 41.8 nmol/L), along with an improved sensitivity against K103N or Y181C than S-DABOs 26 . The molecular modeling study ( Fig. 1 ) indicated that the carbonyl oxygen of C2 side chain of DB02 forms a key H-bond with the backbone (eNHe group) of K103 of HIV-1 RT which acts as essential Figure 1 Structures of S-DABOs and newly designed compounds.
Novel S-DABOs derivatives as potential HIV-1 inhibitorspharmacophore elements favorably contributing to ligand binding 26, 27 . Since the u-phenyl of C2 side chain point at the interface between the enzyme and the solvent, we could conclude that longer and diverse groups are tolerant of this region. The proposed binding mode for DB02 allowed us to anticipate that the introduction of a pyrazol group, which contains both hydrogen bond donor and acceptor, at C2 side chain instead of a carbonyl group might further strengthen the hydrogen interactions with K103 of the viral enzyme RT. This could result in an improved potency against the wild-type or mutant HIV-1 strains. Meanwhile, to develop pep stack and van der Waals' interactions with the amino residues in this hydrophobic region around the C2 side chain, different substituents varying in their size and electronic nature were introduced to the C5 0 and C3 0 position of the pyrazol ring. Thus, a series of novel 2-(((5-akly/aryl-1H-pyrazol-3-yl)me-thyl) thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-one derivatives were designed based on the analysis of the ligandereceptor interactions (Fig. 1 ). In the newly designed analogs, different substituents varying in size and electronic nature were introduced to the u-phenyl of C2 side chain located at the protein-solvent interface region of RT to further investigate the potential interaction. In this paper, we report the synthesis of this novel S-DACOs, the evaluation of their anti-HIV-1 activity and the structureeactivity relationship (SAR) study in detail.
Results and discussion

Chemistry
The target compounds I (1e40) were prepared in a convergent manner by coupling two subunits as depicted in Scheme 1. Following the procedure described previously 21, 25 , the key intermediate b-ketoesters 3 were prepared by exposure of 2-cyclohexylacetic acid 1 to 1,1 0 -carbonyl-diimidazole (CDI)
followed by treatment with different ethyl potassium malonates in the presence of anhydrous MgCl 2 and Et 3 N 28 . Condensation of 3 with thiourea in the presence of EtONa in refluxing EtOH led to substituted uracil 4 which was subjected to S-alkylation in anhydrous DMF with 3-(bromomethyl)-5-R 1 -1H-pyrazole (10) in the presence of K 2 CO 3 to afford the target compounds I (1e40). 10 required for the S-alkylation was prepared from appropriate methyl ketones 5. The addition of methyl ketones 5 to diethyl malonate, followed by the cyclization with hydrazine for the pyrazole ring formation under refluxing condition gave the desired 5-substituted-1H-pyrazole-3-carboxylate (7) over two steps 29, 30 . Halogenation on the pyrazole with NCS produced chlorinated pyrazole 8 in good yield. The ester moiety was then converted into the alcohol 9 by reduction with LiAlH 4 and then bromination with PBr 3 or Br 2 reagent. These synthesized compounds were characterized by physicochemical and spectral means. MS, 1 H NMR, 13 C NMR spectral data were found in agreement with the assigned molecular structures.
Anti-HIV-1 activity evaluation
The novel S-DACO derivatives I (1e40) were tested for their cytotoxicity and anti-HIV-1 activity in C8166 cells infected by the HIV-1 IIIB and compared with nevirapine (NVP), etravirine (ETR) and zidovudine (AZT). The activity data was interpreted in CC 50 (concentration resulting in 50% cell death) values (cytotoxicity), EC 50 (anti-HIV-1 activity) and SI (selectivity index, given by the CC 50 /EC 50 ratio) ( Table 1) . As another control, previously reported compound DB02 25, 26 was included in our test assays for comparison.
As shown in 10.0751 mmol/L respectively. Other 12 compounds (I-01, I-05,  I-08, I-09, I-10, I-11, I-12, I-18, I-20, I-21, I- Based on above anti-HIV-1 results, preliminary SARs of these compounds could be delineated as the following. The side chain connected to C2 position of the pyrimidine ring is a major determinant for the anti-HIV-1 activity of DABOs. Obviously the (1H-pyrazol-3-yl)methyl-thio is favorable to the anti-HIV-1 activities. Compound I-19 displayed an EC 50 value of 0.0334 mmol/L which is similar to that of the reference drug NVP (0.0402 mmol/L). The diverse groups connecting to the C5 0 position of the pyrazole ring are also studied. Changing from hydrogen (I-19) to Me and cyclopropyl gave compounds I-20 and I-21 similar EC 50 value of 0.0277 and 0.0245 mmol/L respectively. However, replacing of the C5 0 hydrogen of I-19 with a tert-butyl decreased the activity for more than 10 folds (I-22 vs. I- 19) . Substituting aryl at the C5 0 position of the pyrazole ring could increase the activity against WT HIV-1 as those compounds which bearing phenyl group at the R 1 position displayed the most potent anti-HIV activity.
Furthermore, the SAR analysis of substitutions on the uphenyl of C2 side chain was explored. Compared with the nonsubstituted compound I-01, introduction of substituent to the phenyl ring seemed to be unfavorable to the HIV-1 inhibitory activities demonstrated by I-02eI-34 activities. However, the exceptions were 4 0 -OH (I-11, EC 50 Z 0.0038 mmol/L, SI Z 25,468) and 4 0 -SMe (I-12, EC 50 Z 0.0118 mmol/L, SI Z 16,949) which enhanced the activities significantly and along with their low cytotoxicity, resulted in extremely high SI. In addition, the monosubstituted phenyl analogs were more potent than disubstituted derivatives (I-2 and I-13 vs. I-14eI-17). For monosubstituted compounds, the activity of para-substituted derivatives was slightly superior to that of meta-substituted derivatives, for example, I-07>I-02, I-08>I-04, I-09>I-05. Meanwhile, the nature of the substituent of the phenyl ring also influenced the antiviral activity of these novel S-DACOs, a clear order of C4 0 -substitution for anti-HIV activity was observed by direct comparison: OH (I-11, SI Z 25,468)>SCH 3 (I-12, SI > 16,949)>H (I-01, SI Z 12,424)>OCH 3 (I-10, SI > 8621)> Cl (I-08, SI Z 4711)>F (I-09, SI Z 3747)>Me (I-07, SI Z 1748)>iPr (I-13, SI Z 212).
Since the introduction of a halogen atom to bioactive molecules could have significant influence on pharmaceutical profiles, the chlorine atom was also introduced to The previous SAR for S-DABOs indicated that the optimal moieties at positions 5 of the pyrimidine nucleus were dependent on the nature of the C2 and C6 side chain 25,26,31e33 . This series clearly showed that inhibitory activity increased proportionally with the modification of the C5 substituent in the order, H < Me < Et. As demonstrated, the 5-Et substituted derivatives (I-10, I-09 and I-01) were 8e27-fold (SI ratio) more active than their 5-Me substituted counterparts (I-36, I-37 and I-35), and 170e731-folds more active than their 5-H substituted counterparts (I-39, I-40 and I-38). This confirmed that the steric bulkiness of C5 substituent is favored to maintain inhibitory activity against HIV-1 replication.
In vitro anti-HIV-1 activity of I-11 and I-12
Based on the results of the first round of screening, we performed further antiviral activity evaluation of I-11 and I-12 as representative compounds and assessed the activity against different HIV-1 strains including wild-type strains (HIV-1 IIIB and HIV-1 Ba-L ), resistant strains (HIV-1 A17 , HIV-1 74V and HIV-1 RF/V82F/184V ) and clinical isolated strains (HIV-1 TC-1 and HIV-1 WAN ). DB02 and NVP were regarded as positive controls. The EC 50 , CC 50 and SI data are summarized in Table 2 . As shown in the Table 2 , I-11 exhibited high potency antiviral replication against most test HIV-1 strains in different cells. In particular, the EC 50 values of I-11 against HIV-1 IIIB , HIV-1 Ba-L and HIV-1 TC-1 , the major isolates from high AIDS prevalence region in China were 0.0043, 0.0485 and 0.0145 mmol/L, respectively. These were about 5e14 times more potent than NVP (EC 50 Z 0.0274, 0.1659 and 0.1992 mmol/L, respectively) and were comparable to that observed with DB02 (EC 50 Z 0.0095, 0.0377 and 0.0151 mmol/L, respectively). The antiviral effect of I-12 is weaker and EC 50 values ranging from 0.0189 to 0.2193 nmol/L. However, for HIV-1 A17 , a multi-drug resistant strain of NNRTIs carrying the K103N and Y181C mutations, I-11, I-12 and DB02 all showed a significantly reduced inhibitory activity with EC 50 values of 2.77, 4.87 and 6.01 mmol/L. Since the new generation of NNRTI, etravirine, showed a better inhibitory activity against K103N/Y181C double mutant HIV-1 strain (EC 50 Z0.050 mmol/L) 34 , more improvements will be required to our compounds.
HIV-1 reverse transcriptase activity assay
Anti-RT activity of I-11 and I-12 were further evaluated by the enzymatic recombinant HIV-1 RT activity assay (Reverse transcriptase assay kit, Roche, Germany). While I-11 showed similar anti-RT activity (IC 50 Z 1.09 AE 0.59 mmol/L) with NVP (IC 50 Z 0.92 AE 0.09 mmol/L) but lower than that of DB02 nearly three times (IC 50 Z 0.28 AE 0.03 mmol/L). I-12 demonstrated lower inhibitory activity (2.27 AE 0.12 mmol/L). Both two compounds have similar dose-dependent pattern in inhibiting HIV-1 RT activity with NVP and DB02 as showed in Fig. 2 .
In vivo pharmacokinetics study
In vivo pharmacokinetic profile of compound I-11 was examined in SpragueeDawley rats (Table 3 and Fig. 3 ). As shown in Table 3 and Fig. 3 , when administered at 5 mg/kg orally, compound I-11 was rapidly absorbed with a T max of 0.5 h, along with a half-life of 2.5 h and a mean residence time (MRT) of 0.554 h. The C max of I-11 was 654 ng/mL (1538 nmol/L), more than 400 times the EC 50 value of anti-HIV-1 activity in vitro (Table 1) . In this experiment, a 10.4% oral bioavailability of I-11 was also observed.
Molecular modeling analysis
To better understand the structure-affinity relationship for this series of derivatives, the represent compounds I-01, I-11, I-23, I-35, I-38 were docked into the NNRTIs binding pocket (NNIBP, PDB code: 1RT2) compared with DB02 using the AutoDock4.2 program. Default parameters were used as described in the Sybyl- 
10. (1) the pyrimidine ring of DB02 and I-11 anchored into the same region of NNIBP through the H-bond formed between the 3-NH moiety on the pyrimidine ring and the main chain oxygen of Lys101. There also existed arene-H interaction between the pyrimidine ring of I-11 and the polarized CH groups of Leu100. (2) The C2 side chain of the two compounds were well accommodated in the pocket surrounded by the side chains of Lys103, Val106, Pro236, Phe227 generating potential van der Waals' interactions and electrostatic interactions to give the advantage of the affinity between inhibitor and RT. In detail, the oxygen atom of C2-b-carbonyl of DB02 and the nitrogen in the pyrazole ring of I-11 made a hydrogenbonding interaction with the NeH function of Lys103. When compared with DB02, one additional H-bond was observed between the NH in the pyrazole ring of I-11 and the main chain oxygen of Lys103 which is good for the activity of compounds. Moreover, the terminal phenyl ring of I-11 extended to the solvent exposure region which might be the main reason of diverse groups connecting to the C5 0 position of the pyrazole ring are tolerant for this region. (3) The C6-u-cyclohexyl group of I-11 and DB02 adopted the lowest energy "chair" conformation positing in the same hydrophobic sub-pocket and exhibiting hydrophobic interactions and van der Waals 0 contacts with the aromatic amino acid residues Tyr181, Tyr188 and Trp229. Compared to DB02, the cyclohexyl group of I-11 extended deeper into this region and formed arene-H with the indol ring of conserved amino acid Trp229 which might be the main reason of giving rise to the high-affinity binding to the NNBIP improving the anti-HIV-1 activity and prevented the loss of activity specifically caused by Y181C mutation.
The results of docking of I-01, I-23, I-35 and I-38 with the WT RT allosteric pocket provided additional explanation for the structureÀactivity relationship of these inhibitors (Fig. 5AeE) . As can be seen from Fig. 5A , the interactions between compound I-01 and RT were almost identical to those of compound I-11 with RT, explains the fact that both I-01 and I-11 have good anti-HIV activity. Further analysis shows that the benzene rings at the end of C2 side chains of I-01 and I-11 reached the solvent-accessible region, the hydrophilic OH at the para-position of the benzene ring of compound I-11 was undoubtedly more favorable for the activity than the hydrophobic aromatic hydrogen of I-01, resulting lower activity of I-01.
Introduction of a chlorine atom at the C4 0 position of the pyrazole ring can be seen from the results in Table 1 . For most compounds, it has little effect on the activity, excepted I-23 with this value had been decreased significantly 15 folds, even though in the binding model I-01 and I-23 behaved similar (comparing Fig. 5A and B) . It is worth noting that although no significant interaction between the chlorine atom and surrounding residues was observed in Fig. 5B , the introduction of a chlorine atom in compound I-23 changed the relative position between pyrazole ring and K103, thus affecting the strength of the hydrogen bond between them. The bond lengths of the two hydrogen bonds between the pyrazole ring of I-23 and K103 are longer (2.07 and 3.27 Å respectively) than that on I-01ecomplex (1.80 and 2.60 Å respectively), providing a rational explanation of the reduced activity of I-23, and suggesting an important role of hydrogenbonding interactions at this position.
In addition, the results of I-35 and I-38 docking with the allosteric pocket of WT RT ( Fig. 5C and D) showed that the C5 substituent of the pyrimidine nucleus would make the inhibitor shift in NNBP, thus significantly affecting the formation of hydrogen bond between pyrazole ring and Lys103, which is considered to be important contributors to the binding affinity between RT inhibitors and enzymes. As shown in Fig. 5C , the introduction of a small methyl group at the C5 position of the pyrimidine ring (compound I-35) will move the pyrazole ring of the inhibitor to the left, cause losing the hydrogen bond between the nitrogen of pyrazole ring with the NÀH of Lys103, as the result, the activity of I-35 was reduced compared with that of I-01. Also, replace 5-Me with a smaller H would cause the two hydrogen bonds between the pyrazole ring of I-38 and K103 disappeared simultaneously (Fig. 5D) , which may be the reason why the efficacy of I-38 against HIV-1 decreased sharply compared with that of I-01.
In summary, the results of the auto docking analysis provided support for the SARs elucidation of our newly designed and synthesized compounds. These facts will be considered in further S-DACOs analog structural design and optimization.
Conclusions
Based on the analysis of the ligandÀreceptor interactions, replacement of the C2-b-carbonyl fragment in the previously reported oxophenethyl-S-DACOs led structures with a pyrazol group resulting in the discovery of a novel series of potent NNRTIs. Most of these new congeners exhibited moderate to excellent activity against wild-type virus with an EC 50 values ranging from 0.4759 to 0.0038 mmol/L. Selected compounds I-11 and I-12 displayed higher anti-HIV-1 activity against laboratory adapted strains and primary isolated strains including different subtypes and tropism strains. The results offer potential in further development of these compounds as a novel class of NNRTIs with improved antiviral efficacy and resistance profile. Furthermore, the selected compound I-11 and I-12 showed similar dosedependent pattern in inhibiting HIV-1 RT activity with NVP confirming that the target of the compounds is RT. Compound I-11 also displayed acceptable in vivo pharmacokinetic properties and bioavailability in rats. The preliminary SARs were discussed and the molecular simulation was performed. The docking study supported our initial hypothesis that the introduction of a pyrazolyl group at C2 position of pyrimidinone could provide an additional hydrogen bond with residue in NNIBP. In addition, the C6-cyclohexyl of these title compounds point to the indole side chain of the highly conserved W229 and forms an interesting CHep interaction which showed vital importance in improving activity against a wide range of clinically relevant HIV-1 mutations. Hence the introduction of a large hydrophobic group at the C6 position of the prymidine ring contributes to the development of new potent NNRTIs against mutant strains. Taking full advantage of the valuable information from SARs analysis, further optimization of this series of compounds aimed at improving drug resistance profiles and exploring the salient features controlling the activity are ongoing in our lab and will be reported in due course.
Experimental
Chemistry
Melting points (m.p.) were determined by a WRS-1 digital melting point instrument (Shanghai, China). 1 H NMR and 13 C NMR spectra were obtained on a Bruker AM 400/300 MHz spectrometer (Fällanden, Switzerland) using dimethyl sulfoxided 6 (DMSO-d 6 ) as solvent. Chemical shifts are reported in d (ppm) units relative to the internal reference tetramethylsilane (TMS). Mass spectra were obtained on an Agilent LC/MSD TOF mass spectrometer (Watertown, MA, USA). The regents and solvents used were all of analytical grades, and were purified and dried by standard methods before use. All air-sensitive reactions were run under nitrogen stream protection. All the reactions were monitored by thin-layer chromatography (TLC) on pre-coated silica gel G plates at 254 nm under a UV lamp using ethyl acetate/petroleum ether as eluents. Flash chromatography separations were obtained on silica gel (300e400 mesh; Qingdao Marine Chemical Factory, Qingdao, China). 5-Alkyl-6-(cyclohexylmethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (4) was prepared as previously reported 25, 27 .
4.1.1. Ethyl 2,4-dioxo-4-subtituted-butanoate (6) Sodium metal (6.9 g, 3.0 mmol) was dissolved in absolute ethanol (40 mL). Diethyl oxalate (1.2 mmol) was added at 25 C followed by a solution of appropriate methyl ketones 5 (1.0 mmol). The resulting mixture was stirred overnight at 25 C. The reaction mixture was quenched by the addition of 1.0 mol/L HCl and extracted with EtOAc (2 Â 40 mL). The combined organic layers were washed successively with water and brine and dried over MgSO 4 . After filtration and concentration in vacuo, ethyl 2,4-dioxo-4-subtituted-butanoate (6) was obtained with yields of 88%e96% which can be used in the following step without further purification.
Ethyl 5-substituted-1H-pyrazole-3-carboxylate (7)
Hydrazine hydrate (1.5 mmol) was added to a solution of ethyl 2,4-dioxo-4-subtituted-butanoate (6) (1.0 mmol) in EtOH (30 mL) and the reaction mixture was refluxed for 3 h. The reaction mixture was cool to room temperature and the solvent was evaporated under reduced pressure. The residue was poured into 25 mL water and ethyl acetate for extraction, the organic layer was washed successively with water and brine, then dried over MgSO 4 , filtered and concentrated in vacuo to give ethyl 5-substituted-1H-pyrazole-3-carboxylate (7) as a pale yellow solid with yields of 85%e90%, which can be used in the following step without further purification.
Ethyl 4-chloro-5-substituted-1H-pyrazole-3-carboxylate (8)
A solution of ethyl 5-substituted-1H-pyrazole-3-carboxylate (7) (1.0 mmol), N-chlorosuccinimide (NCS, 1.5 mmol) in CH 3 CN/ DMF (10 mL/2 mL) was heated to 55 C for 20 h. The reaction mixture was concentrated under reduced pressure and the residue was poured into 25 mL of water and extracted by ethyl acetate. The organic layer was dried over MgSO 4 , filtered and concentrated in vacuo to give ethyl 4-chloro-5-substituted-1H-pyrazole-3-carboxylate (8) as a light brown solid with yields of 40%e60%, which is used in the next step without further purification.
(4-Chloro-5-substituted-1H-pyrazol-3-yl)methanol (9)
LiAlH 4 (1.5 mmol) was added to a 0 C solution of ester 7 or 8 (1.0 mmol) in drying THF (10 mL). The resultant mixture was stirred at 0 C for 2 h. The reaction was quenched by the slow addition of saturate NH 4 Cl. The aqueous layer was extracted with EtOAc and dried over MgSO 4 . After filtration and concentration in vacuo, the residue was purified by flash column chromatography or recrystallization to give alcohol 9A or 9B as a white solid with the yield of 51%e78%.
3-(Bromomethyl)-5-substituted-1H-pyrazole (10)
To a solution of alcohol 9 (1.0 mmol) in CH 3 CN (10.0 mL) was added PBr 3 (1.5 mmol) slowly. The reaction was stirred at refluxing for 2 h. The reaction mixture was then cooled to room temperature and poured into the ice water and extracted with EtOAc (2 Â 40 mL). The combined organic layers were washed successively with water and brine, dried over MgSO 4 . After filtration and concentration in vacuo, the residue was purified by flash column chromatography to give 3-(bromomethyl)-4-chloro-5-substituted-1H-pyrazole (10) (92%e100%) as a white waxy solid.
2-(((5-Substituted-1H-pyrazol-3-yl)methyl)thio)-6-(cyclohexylmethyl)-5-alkyl-pyrimidin-4 (3H)-one I (1-40)
K 2 CO 3 (2.2 mmol) and compound 10 (2.2 mmol) were added to a solution of 2-thiouracil (4) (2 mmol) in anhydrous DMF (8 mL). The mixture was stirred at room temperature for 8e24 h. After TLC (EtOAc/PE) revealed the disappearance of the starting material, the reaction mixture was filtered. The suspension was then diluted with cold water and extracted with ethyl acetate. The combined organic extract was washed with brine, dried with Na 2 SO 4 , and evaporated to furnish crude product, which was purified by flash chromatography or by crystallization to give the pure target compounds I (1-40). 1H, cyclohexyl-H), 2.36e2.38 (m, 2H, CH 2 -cyclohexyl) 68 (s, 1H, pyrazole-H), 7.59e7.62 (m, 1H, Ph-H 
6-(Cyclohexylmethyl)-5-ethyl-2-(((5-phenyl-1H-pyrazol-3-yl)methyl)thio)pyrimidin-4(3H)-one (I-01
6-(Cyclohexylmethyl)-5-ethyl-2-(((5-(m-tolyl)-1H-pyrazol-3-yl)methyl)thio)pyrimidin-4(3H)-one (I-02
2-(((5-(3-Chlorophenyl)-1H-pyrazol-3-yl)methyl)thio)-6-(cyclohexylmethyl)-5-ethyl-pyrimidin-4(3H)-one (I-04
2-(((5-(4-Chlorophenyl)-1H-pyrazol-3-yl)methyl)thio)-6-(cyclohexylmethyl)-5-ethyl-pyrimidin-4(3H)-one (I-08
4.1.6.16. 6-(Cyclohexylmethyl)-2-(((5-(2,4-dimethylphenyl)- 1H-pyrazol-3-yl)methyl)thio)-5-ethyl-pyrimidin-4(3H)-one (I- 16
Molecular docking
Molecular simulations were performed using AutoDock4.2 program 39 . All the molecules for docking were optimized for 5000-generation till the maximum derivative of energy became 0.005 kcal/mol$Å using the Tripos force field. Charges were computed and added according to Gasteiger-Huckel parameters. The published 3D crystal structure of the HIV-1 RT with TNK-651 complex was retrieved from the Protein Data Bank (PDB code: 1RT2). The molecules and proteins were prepared by using the AutoDockTools 1.5.4 (ADT). The bound ligand was extracted from the complexes, water molecules were removed, hydrogen atoms were automatically added, side chain amides and side chains bumps were fixed, and charges and atom types were assigned according to AMBER force field. Then, 100 separate docking calculations were performed using the reported modeling protocol 40 .
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